News | January 29, 2022
DCGI approves Bharat Biotech’s Phase 3 trials for intranasal vaccine
Intranasal vaccines are easier to administer in mass immunisation campaigns and help reduce or stop transmission
Intranasal vaccines are easier to administer in mass immunisation campaigns and help reduce or stop transmission
SOLOSEC is designed to be easy to take and one oral dose contains a complete course of treatment
The artificial cornea is 100% made of non-biological materials and require no co-implantation of donor corneas and it is an ideal option for treating patients with corneal blindness
BPZE1 is the most advanced next-generation pertussis vaccine currently in clinical development
It will be marketed under the brand name Molunamax
The TaqMan SARS CoV-2 Mutation Panel is compatible with real-time PCR instruments already commonly used in laboratories around the world
Authorized booster increases Omicron neutralizing antibody levels approximately 37-fold
GCC Biotech is manufacturing the kits on a public-private partnership (PPP) model
The interim results of Phase 3 clinical trials conducted by CanSinoBIO demonstrated that Convidecia has an efficacy of 95.47% at preventing severe disease 14 days after single-dose vaccination.
The Omicron variant, which was designated a variant of concern by the World Health Organization (WHO), has more than 30 mutations in the spike protein alone
Subscribe To Our Newsletter & Stay Updated
